Skip to main content
Premium Trial:

Request an Annual Quote

Ventana Extends CDx Deal with Bayer

NEW YORK (GenomeWeb News) – Roche's Ventana Medical Systems today announced an extension of an agreement to develop companion diagnostics for Bayer Pharma's targeted therapy projects.

The firms inked an agreement in early 2012 to develop a molecular companion diagnostic for a Bayer antibody-drug conjugate, and today's deal is for the development of diagnostic tests for Bayer's biomarker-targeted therapeutics, Ventana said. The collaboration will make use of Ventana's immunohistochemistry technologies.

As part of the agreement, Ventana will create a team of experts with resources focused exclusively on Bayer projects. Financial and other terms were not disclosed.